Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response-Reference-Cited by-同舟云学术

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response

Published:2015-07-21 Issue:3 Volume:314 Page:237
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Jackson Lisa A.¹,Campbell James D.²,Frey Sharon E.³,Edwards Kathryn M.⁴,Keitel Wendy A.⁵,Kotloff Karen L.²,Berry Andrea A.²,Graham Irene³,Atmar Robert L⁵,Creech C. Buddy⁴,Thomsen Isaac P.⁴,Patel Shital M.⁵,Gutierrez Andres F.⁵,Anderson Edwin L.³,El Sahly Hana M.⁵,Hill Heather⁶,Noah Diana L.⁷,Bellamy Abbie R.⁶

Affiliation:

1. Group Health Research Institute, Seattle, Washington

2. Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore

3. Division of Infectious Diseases, Allergy, and Immunology, Saint Louis University School of Medicine, St Louis, Missouri

4. Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee

5. Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas

6. The EMMES Corporation, Rockville, Maryland

7. Southern Research Institute, Birmingham, Alabama

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant;International Journal of Biological Macromolecules;2024-09

2. Immune-enhancing activity of compound polysaccharide on the inactivated influenza vaccine;Carbohydrate Polymers;2024-07

3. Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by MF59 and AS03-like Adjuvants;Vaccines;2024-05-13

4. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults;Clinical Infectious Diseases;2024-03-27

5. Research progress on emulsion vaccine adjuvants;Heliyon;2024-02